世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ナノ粒子薬物送達システム産業調査レポート 2023年


Nanoparticle Drug Delivery Systems Industry Research Report 2023

当レポートは、ナノ粒子薬物送達システムの世界市場を量的・質的分析の両面から包括的に提示することで、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 図表数 言語
APO Research
エーピーオーリサーチ
2023年8月11日 US$2,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
113 146 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

当レポートは、ナノ粒子薬物送達システムの世界市場を量的・質的分析の両面から包括的に提示することで、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、ナノ粒子薬物送達システムに関する十分な情報に基づいたビジネス上の意思決定を行えるようにすることを目的としています。
ナノ粒子薬物送達システムの市場規模、推計、予測は、2022年を基準年として、2018年から2029年までの期間の履歴データと予測データを考慮し、収益(百万ドル)で提供します。本レポートでは、世界のナノ粒子薬物送達システム市場を包括的に区分しています。種類別、用途別、プレイヤー別の製品に関する地域別市場規模も掲載しています。COVID-19とロシア・ウクライナ戦争の影響は市場規模を推定する際に考慮した。
市場のより詳細な理解のために、本レポートは競合状況、主要競合企業のプロフィール、それぞれの市場ランクを提供している。また、技術動向や新製品開発についても論じています。
本レポートは、企業別、製品タイプ別、用途別、地域別など、さまざまなセグメントにわたる市場全体とサブセグメントの収益に関する情報を提供し、この市場におけるナノ粒子薬物送達システム企業、新規参入企業、業界チェーン関連企業の助けとなります。
主要企業&市場シェアの洞察
本セクションでは、読者は競合する主要企業について理解を深めることができる。本レポートでは、革新的な動向や開発、製品ポートフォリオの強化、M&A、提携、新製品の革新、地理的拡大など、参入企業が存在感を維持するために行っている主要な成長戦略を調査している。事業戦略の他に、本調査には現在の開発状況や主要財務情報も含まれている。読者はまた、2017-2022年の期間における企業別の世界的な収益に関連するデータにアクセスすることができます。この包括的なレポートは、クライアントが最新情報を入手し、ビジネスにおいて効果的な意思決定を行うのに役立つことでしょう。調査レポートでレビューされている著名な企業には以下のようなものがある:
ジョンソン・エンド・ジョンソン
サン・ファーマシューティカル
CSPC
キノンド
テバ
復旦-張江
ザイダス・カディラ
TTYバイオファーマ
パシラ
Luyeファーマ
リーディアント・バイオサイエンス
イプセン
セイヤー・セラピューティクス
ジャズ
アルナイラム
ボシュ・ヘルス
アクロテック・バイオファーマ
武田薬品
キエシ・ファルマチェウティチ
ギリアド・サイエンシズ
製品タイプ別インサイト
世界市場をナノ粒子薬物送達システムのタイプ別に、2029年までの成長予測とともに紹介する。収益の予測は、ナノ粒子薬物送達システムが企業によって調達されるサプライチェーンにおける価格に基づいています。
本レポートでは、各セグメントを調査し、過去のデータを用いて市場規模を提示しています。また、同セグメントが将来もたらすであろう成長機会についても触れている。この調査では、タイプ別、過去期間(2018-2023年)と予測期間(2024-2029年)の収益データを提供しています。
ナノ粒子薬物送達システムのタイプ別セグメント
リポソーム薬物
脂質ナノ粒子薬物
アプリケーションインサイト
本レポートでは、過去期間(2018-2023年)および予測期間(2024-2029年)におけるアプリケーション別の市場規模(収益データ)を掲載しています。
また、ナノ粒子薬物送達システム市場に影響を与える各セグメントの市場動向や消費者行動について概説し、これらが業界の将来にどのような影響を及ぼす可能性があるかについても記載しています。本レポートは、ナノ粒子薬物送達システム市場を牽引している関連市場と消費者動向の理解に役立ちます。
ナノ粒子薬物送達システムの用途別セグメント
病院
小売薬局
その他
地域別展望
本セクションでは、様々な地域と各地域で事業を展開する主要企業に関する主要な洞察を提供する。特定の地域/国の成長を評価する際に、経済、社会、環境、技術、政治的要因が考慮されている。読者は、2018年から2029年までの各地域・国の収益データも手にすることができる。
市場は、北米、欧州、アジア太平洋、南米、中東・アフリカを含む様々な主要地域に区分されている。米国、ドイツ、英国、イタリア、フランス、中国、日本、韓国、東南アジア、インドなどの主要国の詳細な分析は、地域セグメント内でカバーされます。市場推計については、2022年を基準年として、2023年の推計値、2029年の予測収益を提供する予定である。
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
北欧諸国
その他のヨーロッパ諸国
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA
主な推進要因と障壁
本レポートでは、読者が一般的な発展を理解するのに役立つよう、影響力の大きいレンダリング要因とドライバーを調査している。さらに、プレイヤーの行く手を阻む阻害要因や課題も含まれています。これは、ユーザーが気を配り、ビジネスに関連する情報に基づいた意思決定を行うのに役立ちます。また、専門家は今後のビジネス展望にも焦点を当てている。
COVID-19とロシア・ウクライナ戦争の影響力分析
このセクションの読者は、パンデミック、パンデミック後、ロシア・ウクライナ戦争中にナノ粒子薬物送達システム市場のシナリオが世界中でどのように変化したかを理解することができます。この調査は、需要、消費、輸送、消費者行動、サプライチェーン管理などの側面の変化を視野に入れて行われています。また、業界の専門家は、今後数年間、プレーヤーに機会を創出し、業界全体を安定させるのに役立つ主要な要因を強調しています。
本レポートを購入する理由
本レポートは、読者が潜在的な利益を高めるために、業界内の競争と競争環境の戦略を理解するのに役立ちます。また、世界のナノ粒子薬物送達システム市場の競争環境に焦点を当て、主要企業の市場シェア、業界ランキング、競合エコシステム、市場実績、新製品開発、経営状況、事業拡大、買収などを詳細に紹介することで、読者が主要競合企業を特定し、市場の競争パターンを深く理解するのに役立ちます。
本レポートは、関係者がナノ粒子薬物送達システムの世界的な産業状況と動向を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。
本レポートは、利害関係者が競合他社をよりよく理解し、事業における自社の地位を強化するためのより多くの洞察を得るのに役立ちます。競争環境のセクションには、市場シェアと順位(数量と金額)、競合他社のエコシステム、新製品開発、拡大、買収などが含まれます。
本レポートは、斬新な技術統合、機能、市場の最新動向を常に更新しています。
本レポートは、関係者がCOVID-19とロシア・ウクライナ戦争がナノ粒子薬物送達システム産業に与える影響を理解するのに役立ちます。
本レポートは、関係者が世界的にどの地域をターゲットとすべきかについて洞察するのに役立ちます。
本レポートは、関係者がナノ粒子薬物送達システムの採用に関するエンドユーザーの認識について洞察するのに役立ちます。
本レポートは、関係者が市場の主要プレイヤーを特定し、その価値ある貢献について理解するのに役立ちます。
主な章立て
第1章:調査目的、調査方法、データソース、データの相互検証
第2章: レポートのスコープ、各市場セグメント(製品タイプ、用途など)の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介。市場の現状と、短期・中期・長期的にどのような進化を遂げる可能性があるのかについて、ハイレベルな見解を提供しています。
第3章:様々な市場セグメントの製品タイプの分析を提供し、各市場セグメントの市場規模や発展可能性などを網羅し、読者が様々な市場セグメントにおけるブルーオーシャン市場を見つけるのに役立つ。
第4章:様々な市場セグメントのアプリケーションの分析を提供し、各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる川下市場のブルーオーシャン市場を見つけるのを助ける。
第5章:世界市場規模、地域市場規模のエグゼクティブサマリーを紹介し、このセクションではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界の企業が直面する課題とリスク、業界の関連政策の分析を紹介します。
第6章 ナノ粒子薬物送達システム企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などの詳細分析
第7章、第8章、第9章、第10章、第11章:北米、欧州、アジア太平洋、中南米、中東、アフリカの国別セグメント。各地域と主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、生産能力などを紹介しています。
第12章:主要企業のプロフィールを提供し、製品の売上高、収益、価格、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本状況を詳しく紹介する。
第13章:レポートの要点と結論。


ページTOPに戻る


目次

1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Nanoparticle Drug Delivery Systems by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
2.3 Nanoparticle Drug Delivery Systems by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Nanoparticle Drug Delivery Systems Breakdown Data by Type
3.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Type (2018-2023)
3.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2023-2028)
4 Nanoparticle Drug Delivery Systems Breakdown Data by Application
4.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Application (2018-2023)
4.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Nanoparticle Drug Delivery Systems Market Perspective (2018-2029)
5.2 Global Nanoparticle Drug Delivery Systems Growth Trends by Region
5.2.1 Global Nanoparticle Drug Delivery Systems Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Nanoparticle Drug Delivery Systems Historic Market Size by Region (2018-2023)
5.2.3 Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029)
5.3 Nanoparticle Drug Delivery Systems Market Dynamics
5.3.1 Nanoparticle Drug Delivery Systems Industry Trends
5.3.2 Nanoparticle Drug Delivery Systems Market Drivers
5.3.3 Nanoparticle Drug Delivery Systems Market Challenges
5.3.4 Nanoparticle Drug Delivery Systems Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue
6.1.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue (2018-2023)
6.1.2 Global Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2018-2023)
6.2 Global Nanoparticle Drug Delivery Systems Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Nanoparticle Drug Delivery Systems Head office and Area Served
6.4 Global Nanoparticle Drug Delivery Systems Players, Product Type & Application
6.5 Global Nanoparticle Drug Delivery Systems Players, Date of Enter into This Industry
6.6 Global Nanoparticle Drug Delivery Systems Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Nanoparticle Drug Delivery Systems Market Size (2018-2029)
7.2 North America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
7.4 North America Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Nanoparticle Drug Delivery Systems Market Size (2018-2029)
8.2 Europe Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
8.4 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size (2018-2029)
9.2 Asia-Pacific Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
9.4 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Nanoparticle Drug Delivery Systems Market Size (2018-2029)
10.2 Latin America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
10.4 Latin America Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size (2018-2029)
11.2 Middle East & Africa Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
11.4 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Nanoparticle Drug Delivery Systems Introduction
11.1.4 Johnson & Johnson Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Nanoparticle Drug Delivery Systems Introduction
11.2.4 Sun Pharmaceutical Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Nanoparticle Drug Delivery Systems Introduction
11.3.4 CSPC Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Nanoparticle Drug Delivery Systems Introduction
11.4.4 Kinyond Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Nanoparticle Drug Delivery Systems Introduction
11.5.4 Teva Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Nanoparticle Drug Delivery Systems Introduction
11.6.4 Fudan-Zhangjiang Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Nanoparticle Drug Delivery Systems Introduction
11.7.4 Zydus Cadila Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Nanoparticle Drug Delivery Systems Introduction
11.8.4 TTY Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Nanoparticle Drug Delivery Systems Introduction
11.9.4 Pacira Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Nanoparticle Drug Delivery Systems Introduction
11.10.4 Luye Pharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Nanoparticle Drug Delivery Systems Introduction
11.11.4 Leadiant Biosciences Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Nanoparticle Drug Delivery Systems Introduction
11.12.4 Ipsen Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Nanoparticle Drug Delivery Systems Introduction
11.13.4 Sayre Therapeutics Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Nanoparticle Drug Delivery Systems Introduction
11.14.4 Jazz Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Nanoparticle Drug Delivery Systems Introduction
11.15.4 Alnylam Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Nanoparticle Drug Delivery Systems Introduction
11.16.4 Bausch Health Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Nanoparticle Drug Delivery Systems Introduction
11.17.4 Acrotech Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Nanoparticle Drug Delivery Systems Introduction
11.18.4 Takeda Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Nanoparticle Drug Delivery Systems Introduction
11.19.4 Chiesi Farmaceutici Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Nanoparticle Drug Delivery Systems Introduction
11.20.4 Gilead Sciences Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.20.5 Gilead Sciences Recent Development
13 Report Conclusion
14 Disclaimer

 

ページTOPに戻る


 

Summary

This report aims to provide a comprehensive presentation of the global market for Nanoparticle Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanoparticle Drug Delivery Systems.
The Nanoparticle Drug Delivery Systems market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nanoparticle Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanoparticle Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Product Type Insights
Global markets are presented by Nanoparticle Drug Delivery Systems type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Nanoparticle Drug Delivery Systems are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Nanoparticle Drug Delivery Systems segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Nanoparticle Drug Delivery Systems market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Nanoparticle Drug Delivery Systems market.
Nanoparticle Drug Delivery Systems Segment by Application
Hospital
Retail Pharmacy
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Nanoparticle Drug Delivery Systems market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanoparticle Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Nanoparticle Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Nanoparticle Drug Delivery Systems industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanoparticle Drug Delivery Systems.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nanoparticle Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.



ページTOPに戻る


Table of Contents

1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Nanoparticle Drug Delivery Systems by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
2.3 Nanoparticle Drug Delivery Systems by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Nanoparticle Drug Delivery Systems Breakdown Data by Type
3.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Type (2018-2023)
3.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2023-2028)
4 Nanoparticle Drug Delivery Systems Breakdown Data by Application
4.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Application (2018-2023)
4.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Nanoparticle Drug Delivery Systems Market Perspective (2018-2029)
5.2 Global Nanoparticle Drug Delivery Systems Growth Trends by Region
5.2.1 Global Nanoparticle Drug Delivery Systems Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Nanoparticle Drug Delivery Systems Historic Market Size by Region (2018-2023)
5.2.3 Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029)
5.3 Nanoparticle Drug Delivery Systems Market Dynamics
5.3.1 Nanoparticle Drug Delivery Systems Industry Trends
5.3.2 Nanoparticle Drug Delivery Systems Market Drivers
5.3.3 Nanoparticle Drug Delivery Systems Market Challenges
5.3.4 Nanoparticle Drug Delivery Systems Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue
6.1.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue (2018-2023)
6.1.2 Global Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2018-2023)
6.2 Global Nanoparticle Drug Delivery Systems Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Nanoparticle Drug Delivery Systems Head office and Area Served
6.4 Global Nanoparticle Drug Delivery Systems Players, Product Type & Application
6.5 Global Nanoparticle Drug Delivery Systems Players, Date of Enter into This Industry
6.6 Global Nanoparticle Drug Delivery Systems Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Nanoparticle Drug Delivery Systems Market Size (2018-2029)
7.2 North America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
7.4 North America Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Nanoparticle Drug Delivery Systems Market Size (2018-2029)
8.2 Europe Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
8.4 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size (2018-2029)
9.2 Asia-Pacific Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
9.4 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Nanoparticle Drug Delivery Systems Market Size (2018-2029)
10.2 Latin America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
10.4 Latin America Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size (2018-2029)
11.2 Middle East & Africa Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
11.4 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Nanoparticle Drug Delivery Systems Introduction
11.1.4 Johnson & Johnson Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Nanoparticle Drug Delivery Systems Introduction
11.2.4 Sun Pharmaceutical Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Nanoparticle Drug Delivery Systems Introduction
11.3.4 CSPC Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Nanoparticle Drug Delivery Systems Introduction
11.4.4 Kinyond Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Nanoparticle Drug Delivery Systems Introduction
11.5.4 Teva Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Nanoparticle Drug Delivery Systems Introduction
11.6.4 Fudan-Zhangjiang Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Nanoparticle Drug Delivery Systems Introduction
11.7.4 Zydus Cadila Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Nanoparticle Drug Delivery Systems Introduction
11.8.4 TTY Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Nanoparticle Drug Delivery Systems Introduction
11.9.4 Pacira Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Nanoparticle Drug Delivery Systems Introduction
11.10.4 Luye Pharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Nanoparticle Drug Delivery Systems Introduction
11.11.4 Leadiant Biosciences Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Nanoparticle Drug Delivery Systems Introduction
11.12.4 Ipsen Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Nanoparticle Drug Delivery Systems Introduction
11.13.4 Sayre Therapeutics Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Nanoparticle Drug Delivery Systems Introduction
11.14.4 Jazz Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Nanoparticle Drug Delivery Systems Introduction
11.15.4 Alnylam Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Nanoparticle Drug Delivery Systems Introduction
11.16.4 Bausch Health Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Nanoparticle Drug Delivery Systems Introduction
11.17.4 Acrotech Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Nanoparticle Drug Delivery Systems Introduction
11.18.4 Takeda Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Nanoparticle Drug Delivery Systems Introduction
11.19.4 Chiesi Farmaceutici Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Nanoparticle Drug Delivery Systems Introduction
11.20.4 Gilead Sciences Revenue in Nanoparticle Drug Delivery Systems Business (2017-2022)
11.20.5 Gilead Sciences Recent Development
13 Report Conclusion
14 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD(drug)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


APO Research社はどのような調査会社ですか?


 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る